Patients with Parkinson’s disease suffer from a number of unmet needs, which MTPA hopes to resolve with ND0612. Image credit: Shutterstock / PopTika.

Mitsubishi Tanabe Pharma America (MTPA) has announced that a Phase III trial of its Parkinson’s disease (PD) candidate ND0612 has met its primary endpoint.

The multi-centre, randomised, double-blind double-dummy (DBDD), BouNDless trial (NCT04006210) evaluated the efficacy, safety and tolerability of ND0612 (levodopa/carbidopa), compared to oral intermediate-release (IR) levodopa/carbidopa (LD/CD) in people with PD experiencing motor fluctuations.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The results of this trial come after two previous Phase III trials of the candidate were withdrawn, according to GlobalData’s Pharmaceutical Intelligence Centre.

GlobalData is the parent company of the Clinical Trials Arena.

The trial met its primary endpoint and the first four secondary endpoints. These most recent results, which follow positive topline data reported earlier this year, were presented at the International Congress of Parkinson’s Disease and Movement Disorder Society (MDS) in Copenhagen, Denmark, between 27 to 31 August 2023.

See Also:

MTPA president Yasutoshi Kawakami said: “We are thrilled to present these positive results from our ongoing Phase III BouNDless trial, as they help us further understand the effect of ND0612 in people with Parkinson’s disease experiencing motor fluctuations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The outcome of this trial exemplifies our commitment to continue recognising the unmet needs of people living with this disease, and we look forward to sharing additional study findings with the scientific community.”

Trial results

Patients in the experimental group of ND0612 demonstrated favourable efficacy over IR-LD/CD. Data showed a statistically significant increase (p<0.0001) of 1.72 hours in “ON” time without troublesome dyskinesia. The trial also demonstrated positive and clinically meaningful results for the first four secondary endpoints, including a reduction of “OFF” time (p<0.0001).

Infusion site reactions were the most reported with 57% for ND0612 and 43% for IR-LD/CD. Certain infusion site reactions, including haematoma, infection, erythema, pain and infusion eschar, were more frequent in the ND0612 group compared to oral LD/CD.

The safety profile of ND0612 was consistent with that of oral standard of care LD/CD. 6.3% of study participants discontinued the trial during the DBDD period due to any reason – including 5.5% due to adverse events.

About ND0612

ND0612 is an investigative drug and device combination therapy for people with Parkinson’s disease (PD) experiencing motor fluctuations. It is administered as a continuous, 24-hour-a-day subcutaneous (SC) infusion of liquid LD/CD.

MTPA subsidiary NeuroDerm is leading the development of ND0612. MTPA to commercialise the therapy in the US subject to receiving regulatory approval.